ethyl 5-chloro-β-oxo-α,2-bis(phenylmethoxy)benzenepropanoate | 103620-88-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 5-chloro-β-oxo-α,2-bis(phenylmethoxy)benzenepropanoate
• 英文别名: Ethyl 5-chloro-beta-oxo-alpha,2-bis(phenylmethoxy)benzenepropanoate；ethyl 3-(5-chloro-2-phenylmethoxyphenyl)-3-oxo-2-phenylmethoxypropanoate
• CAS: 103620-88-8
• 化学式: C₂₅H₂₃ClO₅
• 分子量: 438.908
• InChiKey: WHUPAPNBHLHGBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 5-chloro-β-oxo-α,2-bis(phenylmethoxy)benzenepropanoate 在 钯 作用下， 以 乙酸乙酯 为溶剂， 反应 2.0h， 以affording 0.293 g (69%) of 6-chloro-3,4-dihydroxy-2H-1-benzopyran-2-one as white solid的产率得到6-氯-3,4-二羟基-2H-1-苯并吡喃-2-酮
  参考文献：
  名称：

  Aci-reductone compounds belonging to the 6,7-disubstituted-3,4-dihydro

  摘要：

  本发明涉及一种新型苯并吡喃酮酸还原酮化合物，其化学式为I，其中X和Y从包括H（除非X和Y不是H，除非另有说明）、Cl或其他卤素、OH、直链或支链C.sub.1-C.sub.6烷基或烷氧基或苯基或苯氧基等的群体中选择，例如苯基或叔丁基等。本发明还提供了化学式I中X，Y=OCH.sub.2 O的化合物。本发明的化合物在治疗或预防血栓栓塞性疾病方面具有用途。

  公开号：

  US04845121A1
• 作为产物：
  描述：

  5-氯-2-羟基苯甲酸甲酯 在 potassium carbonate 、 lithium diisopropyl amide 作用下， 以 丙酮 为溶剂， 反应 8.0h， 生成 ethyl 5-chloro-β-oxo-α,2-bis(phenylmethoxy)benzenepropanoate
  参考文献：
  名称：

  Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3-dihydrobenzofuran analog

  摘要：

  A synthetic method for the preparation of aci-reductone 6-chloro-3,4-dihydroxy-2H-1-benzopyran-2-one (3) from 5-chlorosalicylate is presented. In human platelets, the benzopyranone derivative 3, clofibric acid (1), and the 2,3-dihydrobenzofuran analogue 4 inhibited aggregation and serotonin secretory responses to adenosine diphosphate (ADP) with a rank order of potency 3 greater than or equal to 4 greater than 1. Only analogues 3 and 4 consistently blocked the aggregatory responses (greater than 50%) to arachidonic acid (AA) and U46619, a thromboxane A2 agonist. Further, the rank order of inhibitory potency against U46619-induced serotonin secretion was 4 greater than 3 greater than 1. Benzopyranone 3 is of interest since it was the most potent inhibitor of thrombin-induced [3H]AA release (3 much greater than 4 = 1) and more potent than 1 or 4 for the blockade of the ADP- or AA-mediated pathway of platelet aggregation.

  DOI：

  10.1021/jm00161a007

文献信息

• WITIAK DONALD T., KIM SUNG K., FELLER DENNIS R., ROMSTEDT KARL J.
  作者：WITIAK DONALD T., KIM SUNG K., FELLER DENNIS R., ROMSTEDT KARL J.

  DOI：——

  日期：——
• WITIAK D. T.; KIM SUNG K.; ROMSTEDT K.; NEWMAN H. A. I.; FELLER D. R., J. MED. CHEM., 29,(1986) N 11, 2170-2174
  作者：WITIAK D. T.、 KIM SUNG K.、 ROMSTEDT K.、 NEWMAN H. A. I.、 FELLER D. R.

  DOI：——

  日期：——
• US4845121A
  申请人：——

  公开号：US4845121A

  公开（公告）日：1989-07-04
• Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3-dihydrobenzofuran analog
  作者：Donald T. Witiak、Sung K. Kim、Karl Romstedt、Howard A. I. Newman、Dennis R. Feller

  DOI：10.1021/jm00161a007

  日期：1986.11

  A synthetic method for the preparation of aci-reductone 6-chloro-3,4-dihydroxy-2H-1-benzopyran-2-one (3) from 5-chlorosalicylate is presented. In human platelets, the benzopyranone derivative 3, clofibric acid (1), and the 2,3-dihydrobenzofuran analogue 4 inhibited aggregation and serotonin secretory responses to adenosine diphosphate (ADP) with a rank order of potency 3 greater than or equal to 4 greater than 1. Only analogues 3 and 4 consistently blocked the aggregatory responses (greater than 50%) to arachidonic acid (AA) and U46619, a thromboxane A2 agonist. Further, the rank order of inhibitory potency against U46619-induced serotonin secretion was 4 greater than 3 greater than 1. Benzopyranone 3 is of interest since it was the most potent inhibitor of thrombin-induced [3H]AA release (3 much greater than 4 = 1) and more potent than 1 or 4 for the blockade of the ADP- or AA-mediated pathway of platelet aggregation.
• Aci-reductone compounds belonging to the 6,7-disubstituted-3,4-dihydro
  申请人：The Ohio State University Research Foundation

  公开号：US04845121A1

  公开（公告）日：1989-07-04

  The present invention relates to novel benzopyranone aci-reductone compounds of the formula I wherein X and Y are selected from the group comprising H (except that X and Y are not both H, unless otherwise indicated) Cl or other halogen, OH, a straight or branched C.sub.1 -C.sub.6 alkyl or alkoxy group or phenyl or phenyloxy groups, such as, for example a phenyl or a tertiary butyl group. The invention also provides for compounds of the general formula I wherein X, Y=OCH.sub.2 O. ##STR1## The compounds of the invention are useful in the treatment or prevention of thromboembolic disorders.

  本发明涉及一种新型苯并吡喃酮酸还原酮化合物，其化学式为I，其中X和Y从包括H（除非X和Y不是H，除非另有说明）、Cl或其他卤素、OH、直链或支链C.sub.1-C.sub.6烷基或烷氧基或苯基或苯氧基等的群体中选择，例如苯基或叔丁基等。本发明还提供了化学式I中X，Y=OCH.sub.2 O的化合物。本发明的化合物在治疗或预防血栓栓塞性疾病方面具有用途。